H.R. 4274 (112th): BPCA and PREA Reauthorization Act of 2012

Introduced:
Mar 28, 2012 (112th Congress, 2011–2013)
Status:
Died (Referred to Committee)
Sponsor
Mike Rogers
Representative for Michigan's 8th congressional district
Party
Republican
Text
Read Text »
Last Updated
Mar 28, 2012
Length
22 pages
Related Bills
H.R. 5651 (Related)
Food and Drug Administration Reform Act of 2012

Passed House
Last Action: May 30, 2012

 
Status

This bill was introduced on March 28, 2012, in a previous session of Congress, but was not enacted.

Progress
Introduced Mar 28, 2012
Referred to Committee Mar 28, 2012
 
Full Title

To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003.

Summary

No summaries available.

Cosponsors
2 cosponsors (2D) (show)
Committees

House Energy and Commerce

Health

The committee chair determines whether a bill will move past the committee stage.

 
Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Widget

Get a bill status widget for your website »

Citation

Click a format for a citation suggestion:

Notes

H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.


3/28/2012--Introduced.
BPCA and PREA Reauthorization Act of 2012 - Makes permanent the provisions of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act of 2003 (PREA).
Amends the Federal Food, Drug, and Cosmetic Act to revise provisions concerning pediatric research requirements and the granting of exclusivity.
Extends the period for mandatory reporting of adverse events to the Office of Pediatric Therapeutics to 18 months after an approved label change.
Requires a product sponsor to submit an Initial Pediatric Plan as part of the drug application process and sets forth the process for such submission.
Authorizes the Secretary of Health and Human Services (HHS) to: (1) grant a deferral extension, and sets forth the conditions for such deferral; and (2) issue a non-compliance letter to a product sponsor failing to meet post-marketing requirements, and requires the product sponsor to respond in writing.
Authorizes the Pediatric Review Committee to review deferral extensions.
Requires the Office of Pediatric Therapeutics to include a neonatologist and pediatric epidemiologist.
Reauthorizes the Pediatric Advisory Committee and the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.


No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 4274 (112th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus